PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
The Knowledge Group
 

Company Overview

Contact Info & Offices

Press Releases

The Knowledge Group

Press Release


Receive press releases from The Knowledge Group: By Email RSS Feeds:

Dean L. Fanelli, Ph.D., Partner, Seyfarth Shaw LLP, to Speak at TKG’s Understanding the BPCIA Litigation Pathway Amidst the Increasing Biosimilar Disputes Live Webcast


New York, NY, August 09, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Dean L. Fanelli, Ph.D., Partner, Seyfarth Shaw LLP will speak at The Knowledge Group’s webcast entitled: “Understanding the BPCIA Litigation Pathway Amidst the Increasing Biosimilar Disputes Live Webcast.” This event is scheduled for November 6, 2017 from 12:00 PM - 2:00 PM (ET).
For further details, please visit:

https://www.theknowledgegroup.org/webcasts/legal/intellectual-property-law/understanding-the-bpcia-litigation-pathway

About Dean L. Fanelli, Ph.D.

Dean L. Fanelli, Ph.D. is a partner in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington, D.C. office. Dr. Fanelli’s expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions, and inter partes review and post grant review proceedings. Dr. Fanelli also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act, and he regularly handles IP issues attendant to mergers, acquisitions, and financing for life sciences companies as well as ANDA analyses associated with Hatch-Waxman paragraph IV litigation.

Dr. Fanelli received his J.D. from The George Washington University Law School and received his Ph.D. in organic chemistry from Temple University, where he studied the syntheses of biologically active amino acids and amino acid derivatives under the supervision of Dr. Franklin A. Davis.

About Seyfarth Shaw LLP

Seyfarth Shaw LLP has more than 850 attorneys and provides a broad range of legal services in the areas of intellectual property, labor and employment, employee benefits, litigation, corporate and real estate. With offices in Atlanta, Boston, Chicago, Houston, London, Los Angeles, Melbourne, New York, Sacramento, San Francisco, Shanghai, Sydney and Washington, D.C., Seyfarth’s clients include over 300 of the Fortune 500 companies and reflect virtually every industry and segment of the economy. A recognized leader in delivering value and innovation for legal services, Seyfarth’s acclaimed SeyfarthLean client service model has earned numerous accolades from a variety of highly respected third parties, including industry associations, consulting firms and media. For more information, please visit www.seyfarth.com.

Event Synopsis:

The Biologics Price Competition and Innovation Act (BPCIA) encourages competition and innovation in the biologics market by providing an abridged pathway for the approval of a biosimilar license application along with a twelve-year market exclusivity. The BPCIA also determines patent infringement disputes by setting out a process and addresses potential litigation following a license application. To streamline biosimilar litigation, the BPCIA implements patent statutes that introduce a new artificial patent infringement act, requires information exchange cycles, envisions two waves of litigation, and restricts patent declaratory judgment actions under certain conditions.

Biosimilar litigation is expected to rise as the number of drug manufacturers considering the addition of biosimilars to their drug product portfolios, continues to grow. To dodge costly pitfalls and irreversible mistakes, a complete understanding of the BPCIA litigation pathway should be considered.

The Knowledge Group has assembled a panel of key thought leaders and professionals to help the audience better comprehend the BPCIA Litigation landscape amidst the increasing Biosimilar Disputes. This panel will also present an in-depth analysis and understanding on the current issues surrounding biosimilar litigation and will provide the audience with practical strategies in bringing out the best in these lawsuits in a rapidly evolving legal climate.

Key topics include:
· An Overview of the BPCIA
· The BPCIA Litigation Pathway
· Notable Cases
· Practical Litigation Strategies
· Trends, Developments and Updates

About The Knowledge Group, LLC/The Knowledge Congress Live Webcast Series

The Knowledge Congress was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org/
Contact Information
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
Contact
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org

Click here to view the company profile of The Knowledge Group
Click here to view the list of recent Press Releases from The Knowledge Group
Promote Your Business